Determinants of Antibody Response to a Third SARS-CoV-2 mRNA Vaccine Dose in Solid Organ Transplant Recipients: Results from the Prospective Cohort Study COVAC-Tx.
Daniel BalsbyAnna Christine NilssonSören MöllerSusan Olaf LindvigJesper Rømhild DavidsenRozeta AbaziMikael Kjær PoulsenInge Kristine HoldenUlrik Stenz JustesenClaus BistrupIsik Somuncu JohansenPublished in: Vaccines (2022)
Although the third dose of the BNT162b2 vaccine improved humoral responses among SOT non-responders following the second dose, the overall response remained low, and 22.1% did not develop any response. Patients at risk of a diminished vaccine response require repeated booster doses and alternative treatment approaches.